Investigating Streptococcus pyogenes-Produced Bioactive Secondary Metabolites by Gas Chromatography-Mass Spectrometry (GC-MS) and Evaluating Its Antimicrobial Effects

Abstract

Background:

With a prevalence of 15% to 30% in paediatric pharyngitis, Streptococcus pyogenesis is the most prevalent and consequential bacterial cause of this condition. Although the typical laboratory test for microbiologic confirmation of pharyngitis involves growing a culture from a throat swab specimen, this process takes a long time and means that adequate therapy is delayed. S. pyogenes pharyngitis can cause both immediate and long-term problems if not addressed. Here, we detailed the volatile metabolomes of Staphylococcus pyogenes and related oropharyngeal colonising bacteria. We present evidence to back future breath-based diagnostic testing for streptococcal pharyngitis and propose potential biomarkers that differentiate S. pyogenes from other species. Cellular activity, maintenance, and growth rely on metabolites, which are tiny molecules that take part in metabolic activities. Metabolites typically have concentrations spanning multiple orders of magnitude and a molecular weight ranging from 50 to 1500 Da. Metabolite sensitivity to many environmental factors contributes to the metabolome's high degree of dynamic and time-dependent nature.

Aims and Objectives:

The researchers in this lab set out to identify the antibacterial bioactivity of Streptococcus pyogenes's chemical components and learn more about their biological activity.

Method:

Isolation of Streptococcus pyogenes was accomplished by collecting swabs from children afflicted with streptococcal pharyngitis at Babylon Hospital for Women and Children. Following incubation of the samples in stationary culture at 37°C for 24 hours, headspace samples were taken. Every bacterial species was cultured in the same glassware using the same medium. Analysis and concentration of volatile substances: Gas chromatography-mass spectrometry was used to concentrate and separate volatile metabolites. The biological components, sometimes known as bioactive chemicals, were examined in this study using gas chromatography–mass spectrometry (GC–MS) methods. On top of that, an experimental laboratory was used to assess the efficacy of Streptococcus pyogenes's ethanolic extract against microorganisms.

Results:

We experimentally identified the presence of the following bioactive components using GC-MS analysis on Streptococcus pyogenes: 3-Methylbutyraldehyde, 1,1-Dimethoxynonane, 2-Ethyl-1-butanol, 2,2'-Diaminodiethylamine, diethyl 2-(aminomethylene)malonate, N-ethenylmethanimine, Pyrazine, 2,5-diethyl, 5-Ethyl-2,3-dimethylpyrazine, 4H-imidazo[4,5-c]pyridin-4-one,  2,6-Dimethyl-1-heptene, 2-Nonanone, 5-ethyl. Streptococcus pyogenes was tested for its potential antibacterial effects against five harmful bacteria by analysing its secondary metabolites. This study looked at five distinct infections and how effectively the standard antibiotics AM-Amikacin and CTX-Cefotaxime worked, in comparison to an ethanolic extract of Streptococcus pyogenes. Enterococcus faecalis (16.00±0.32, 26.09±0.25, and 20.71±0.24), Escherichia coli (13.60±0.18, 19.54±0.22, and 17.00±0.20), Bacillus subtilis (17.81±0.20, 21.00±0.23, and 22.64±0.24), Proteus mirabilis (21.65±0.23, 28.07±0.25, and 25.00±0.24), and Staphylococcus epidermidis (19.00±0.22, 24.07±0.25, and 21.89±0.20). Streptococcus pyogenes metabolites were shown to show remarkable activity against Proteus mirabilis, with a mean value of (21.65±0.23).